NU 553 Unit 1 Exam Questions With Correct
Answers
first |step |in |prescribing |process |- |CORRECT |ANSWER✔✔-diagnosing
who |regulates |authority |to |prescribe |- |CORRECT |ANSWER✔✔-state |board |of |nursing
who |regulates |prescription |and |OTC |meds |- |CORRECT |ANSWER✔✔-FDA
4 |steps |to |legal |right |to |prescribe |- |CORRECT |ANSWER✔✔-1: |earn |academic |degree
2: |certification |for |your |population
3: |license |that |conveys |scope |of |practice |and |legal |authority |
4: |obtain |NPI |(buying |meds/supplies) |and |DEA |# |(for |controlled |substances
5 |general |prescribing |principles |- |CORRECT |ANSWER✔✔--benefits |outweigh |risks/adverse |
events |
-drug |therapy |should |be |individualized
-drug |effects |on |quality |of |life |should |be |considered
-demographics: |gender |(females |have |higher |percentages |of |fat), |race, |age, |genetics |
[metabolism]
-off |label |prescribing |is |acceptable |if |there |is |evidence |based |practices |showing |success
considerations |for |pregnancy |- |CORRECT |ANSWER✔✔--absorption |of |meds |slow |down |
-fetus |becomes |susceptible |to |meds |at |14 |days |after |conception
, 9 |elements |of |a |prescription |- |CORRECT |ANSWER✔✔--2 |pt |identifiers |(name |& |DOB)
-name |of |med, |dose, |and |formulation |(tab, |capsule, |elixir)
-quantity/dose, |route, |frequency, |duration
-indication |(not |required |but |suggested)
-quantity |to |be |given
-refills
-provider |credentials, |signature, |date, |and |contact |info
-NPI |#
-DEA |# |for |controlled |substances
how |should |controlled |substances |be |disposed |of |properly? |- |CORRECT |ANSWER✔✔-drug |
takeback |program
phase |of |clinical |trial: |preclinical |- |CORRECT |ANSWER✔✔-lab |and |animal |studies
phase |1 |of |clinical |trial |- |CORRECT |ANSWER✔✔-safety |study |with |20-80 |people
phase |2 |of |clinical |trial |- |CORRECT |ANSWER✔✔-safety |study |to |identify |side |effects |and |
measure |effectiveness
100-300 |people
phase |3 |of |clinical |trial |- |CORRECT |ANSWER✔✔-measure |effectiveness |and |monitor |side |
effects |
1,000 |-3,000 |people
phase |4 |of |clinical |trial |- |CORRECT |ANSWER✔✔-monitor |long |term |side |effects
Answers
first |step |in |prescribing |process |- |CORRECT |ANSWER✔✔-diagnosing
who |regulates |authority |to |prescribe |- |CORRECT |ANSWER✔✔-state |board |of |nursing
who |regulates |prescription |and |OTC |meds |- |CORRECT |ANSWER✔✔-FDA
4 |steps |to |legal |right |to |prescribe |- |CORRECT |ANSWER✔✔-1: |earn |academic |degree
2: |certification |for |your |population
3: |license |that |conveys |scope |of |practice |and |legal |authority |
4: |obtain |NPI |(buying |meds/supplies) |and |DEA |# |(for |controlled |substances
5 |general |prescribing |principles |- |CORRECT |ANSWER✔✔--benefits |outweigh |risks/adverse |
events |
-drug |therapy |should |be |individualized
-drug |effects |on |quality |of |life |should |be |considered
-demographics: |gender |(females |have |higher |percentages |of |fat), |race, |age, |genetics |
[metabolism]
-off |label |prescribing |is |acceptable |if |there |is |evidence |based |practices |showing |success
considerations |for |pregnancy |- |CORRECT |ANSWER✔✔--absorption |of |meds |slow |down |
-fetus |becomes |susceptible |to |meds |at |14 |days |after |conception
, 9 |elements |of |a |prescription |- |CORRECT |ANSWER✔✔--2 |pt |identifiers |(name |& |DOB)
-name |of |med, |dose, |and |formulation |(tab, |capsule, |elixir)
-quantity/dose, |route, |frequency, |duration
-indication |(not |required |but |suggested)
-quantity |to |be |given
-refills
-provider |credentials, |signature, |date, |and |contact |info
-NPI |#
-DEA |# |for |controlled |substances
how |should |controlled |substances |be |disposed |of |properly? |- |CORRECT |ANSWER✔✔-drug |
takeback |program
phase |of |clinical |trial: |preclinical |- |CORRECT |ANSWER✔✔-lab |and |animal |studies
phase |1 |of |clinical |trial |- |CORRECT |ANSWER✔✔-safety |study |with |20-80 |people
phase |2 |of |clinical |trial |- |CORRECT |ANSWER✔✔-safety |study |to |identify |side |effects |and |
measure |effectiveness
100-300 |people
phase |3 |of |clinical |trial |- |CORRECT |ANSWER✔✔-measure |effectiveness |and |monitor |side |
effects |
1,000 |-3,000 |people
phase |4 |of |clinical |trial |- |CORRECT |ANSWER✔✔-monitor |long |term |side |effects
